title: Metabolism and Action of 25-Hydroxy-19-nor-Vitamin D₃ in Human Prostate Cells.
abstract: Since the discovery of 1α,25(OH)2D3 in the early 1970s, it has been widely accepted that this metabolite is responsible for the biological actions of vitamin D. Likewise, we have assumed that 25(OH)-19-nor-D3-dependent growth inhibition of human prostate PZ-HPV-7 cells was the result of its subsequent conversion to 1α,25(OH)2-19-nor-D3, catalyzed by CYP27B1 within the prostate cells. However, further in vitro studies in a reconstituted system using recombinant CYP27B1 revealed that 25(OH)-19-nor-D3 was hardly converted to 1α,25(OH)2-19-nor-D3 by the enzyme. The kinetic analysis of 1α-hydroxylation of 25(OH)D3 and 25(OH)-19-nor-D3 demonstrated that the k(cat)/K(m) for 25(OH)-19-nor-D3 is less than 0.1% of that for 25(OH)D3. When 25(OH)-19-nor-D3 was added to cultured PZ-HPV-7 cells, eight metabolites were detected, while no 1α,25(OH)2-19-nor-D3 was found. In addition, the time course of VDR translocation into the nucleus induced by 100 nM 25(OH)-19-nor-D3, and the subsequent transactivation of CYP24A1 gene were almost identical to those induced by 1 nM 1α,25(OH)2-19-nor-D3. These results strongly suggest that 25(OH)-19-nor-D3 binds directly to VDR as a ligand to transport VDR into the nucleus to induce CYP24A1 gene transactivation. Furthermore, knockdown of CYP27B1 gene did not affect the antiproliferative activity of 25(OH)-19-nor-D3, whereas VDR knockdown attenuated the effect, suggesting that the antiproliferative activity of 25(OH)-19-nor-D3 is VDR dependent but CYP27B1 independent. Finally, our recent studies using the same cell line demonstrate that 25(OH)D3 can act as a VDR agonist to induce gene transactivation. These findings suggest that vitamin D analogs without 1α-hydroxyl group could be developed as drugs for osteoporosis or cancer treatment.
authors.affiliation: Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan; Department of Biochemistry, Fujita Health University for Medical Science, Toyoake, Japan.
authors.forename: Eiji
authors.initials: E
authors.lastname: Munetsuna
authors.affiliation: Faculty of Pharmaceutical Sciences, Teikyo University, Tokyo, Japan.
authors.forename: Atsushi
authors.initials: A
authors.lastname: Kittaka
authors.affiliation: Clinical Translational Science Institute and Department of Medicine, Boston University School of Medicine, Boston, Massachusetts, USA.
authors.forename: Tai C
authors.initials: TC
authors.lastname: Chen
authors.affiliation: Department of Biotechnology, Faculty of Engineering, Toyama Prefectural University, Toyama, Japan. Electronic address: tsakaki@pu-toyama.ac.jp.
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Sakaki
mesh_terms: D000970:Antineoplastic Agents / Q000494:pharmacology; D049109:Cell Proliferation; D002762:Cholecalciferol / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology; D006801:Humans; D008297:Male; D015394:Molecular Structure; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000378:metabolism*; D018167:Receptors, Calcitriol
chemical_list: D000970:Antineoplastic Agents; D018167:Receptors, Calcitriol; D002762:Cholecalciferol
keywords: 19-nor-Vitamin D; Antiproliferative activity; CYP24A1; CYP27B1; Cytochrome P450; Prostate cancer; Vitamin D; Vitamin D receptor